Anastrozole versus progestins/tamoxifen.
Beat
Thuerlimann
T
Department of Internal Medicine, Division Oncology/Haematology, Kantonsspital, St. Gallen, Switzerland. beat.thuerlimann@kssg.ch
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D005544:Forecasting; D006801:Humans; D015337:Multicenter Studies as Topic; D009570:Nitriles / Q000627:therapeutic use*; D011372:Progestins / Q000627:therapeutic use*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D011372:Progestins; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole